- Histology-Agnostic Biomarkers in GI Malignancies
- Biomarker-Driven Treatment of Advanced Colorectal Cancer
- Biomarker-Driven Treatment of Gastric, Esophageal, Gastroesophageal Junction, Pancreatic, and Biliary Tract Cancers
- Live Audience Question and Answer Session
Date / Time
David H. Ilson, MD, PhD
Professor of Medicine
Weill Cornell Medical College
Memorial Sloan Kettering Cancer Center
New York, New York
John L. Marshall, MD
Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Eric Van Cutsem, MD, PhD
Professor of Medicine
University of Leuven
Head, Digestive Oncology Unit
University Hospital Gasthuisberg
This program is intended for global physicians and other healthcare professionals who treat and manage patients with gastrointestinal cancers.
Upon completion of this activity, participants should be able to:
- Apply the available data and expert recommendations to determine which biomarkers should be assessed in your patients with gastrointestinal malignancies
- Plan therapeutic strategies for patients with gastrointestinal malignancies based on predictive biomarker assessment
- Evaluate the clinical validity, utility, and differences among single biomarker companion diagnostics and available comprehensive genomic testing platforms using next-generation sequencing
- Appraise ongoing clinical trials for novel biomarker-driven treatment strategies in gastrointestinal malignancies for patient counsel and potential enrollment
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.